February 7, 2009 -- ChinaBio® Today began a series of articles that will take a broad look at the current status of China life science, finding reason for optimism despite the economic crisis; we also concluded our three-part series on the recently finalized major revision of China’s patent statutes; Genesis Pharmaceuticals will pay $12.2 million to acquire Hongrui Pharma; RHEI Pharma optioned the China rights for Invisicare from Skinvisible; Shanghai Fosun Pharmaceutical upped its stake in Tongjitang Chinese Medicines to 13.2%; and Lotus Pharma paid 180 million RMB ($26.3 million) to purchase land use rights in Inner Mongolia for facilities and a pharma park. More details...
